STOCK TITAN

MAIA Biotechnology to Participate in H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

CHICAGO--(BUSINESS WIRE)-- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs, announced today that the management team will participate in the H.C. Wainwright 24th Annual Global Investment Conference that will be held September 12th – 14th.

The MAIA team is scheduled to present on September 12th at 7:00 am ET and will host investor meetings at the Conference through September 14th.

A webcast of the presentation will be available on the News & Events page of the Investors section of the Company's website. A replay of the webcast will be available for 30 days following the event.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

MAIA Biotechnology

Joseph McGuire

Chief Financial Officer

jmcguire@maiabiotech.com

904-228-2603



ICR Westwicke

Stephanie Carrington

Stephanie.Carrington@westwicke.com

646-277-1282

Source: MAIA Biotechnology, Inc.

MAIA Biotechnology Inc

NYSE:MAIA

MAIA Rankings

MAIA Latest News

MAIA Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services

About MAIA

maia biotechnology, inc. is a targeted therapy, immune-oncology company, focused on development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. a privately-held company based in chicago, maia is led by a passionate, principled and highly experienced management team with significant drug development experience, committed to advancing promising agents into trials in humans clinical trials. maia’s business strategy is designed to advance a strong value proposition for its portfolio of potentially novel compounds. maia controls risk and enhances its opportunity for success by diversifying and generating this portfolio of assets with a variety of compounds with novel mechanisms of action which have potential activity in multiple tumor types. maia’s business model involves placing drug candidates in their own dedicated, r&d focused subsidiary company, which is supported by the common infrastru